STRC Research

Givinostat mARC1 2 Hydroxamate Bypass

4 min read

Givinostat mARC1/2 Hydroxamate Bypass

Distilled from DR1 — Pharmacochaperone Clinical Precedents §4 + cross-cutting §1. The single regulatory data point that makes a hydroxamic-acid lead viable for chronic pediatric dosing — and prescribes the in-vitro metabolic-assay package needed for the IND.

The principle

Hydroxamic acids (R-CONHOH) carry two well-known historical liabilities:

  1. Lossen rearrangement → mutagenicity. CYP450-mediated oxidation of the hydroxamate yields nitrenes/isocyanates with DNA-reactive potential. Drove decades of “avoid this moiety” medicinal-chemistry folklore (Zileuton hepatotoxicity warnings; Panobinostat black-box).
  2. Hepatotoxicity. CYP-driven generation of reactive intermediates concentrates damage at the liver.

Givinostat (Duvyzat, Italfarmaco) received FDA approval March 2024 for Duchenne Muscular Dystrophy in patients ≥ 6 yo. It is a phenylhydroxamic-acid pan-HDAC inhibitor (MW ~430). It cleared chronic pediatric safety review because its primary metabolic clearance does not go through CYP450:

  • mARC1 and mARC2 (mitochondrial amidoxime reducing components) reduce the hydroxamic acid head R-CONHOH → R-CONH₂ (amide).
  • The amide is then hydrolyzed by carboxylesterases in plasma to the parent acid.

Neither step generates Lossen-rearrangement intermediates. Givinostat preclinical genotoxicity package was clean. Phase 3 EPIDYS (four-stair-climb test, 72 weeks): acceptable safety profile in chronic pediatric dosing; primary AEs were diarrhea and dose-dependent thrombocytopenia.

What the FDA expects in the IND package

For any hydroxamate-headed candidate, DR1 §1 prescribes:

  1. mARC1/2 in-vitro reduction assay — recombinant or hepatocyte-fraction-isolated mARC1/2 + NADH cofactor + candidate compound. Quantify rate of hydroxamate → amide conversion.
  2. Standard CYP microsomal panel — to demonstrate CYP is not the dominant path.
  3. Genotoxicity — Ames + micronucleus baseline (any hydroxamate will be challenged here; Givinostat’s clean panel is the precedent).
  4. Hepatocyte-stability — primary human hepatocytes, parent disappearance + metabolite ID via LC-MS.

Demonstrating a clean CYP-bypass via mARC1/2 is the regulatory key that converts a hydroxamic-acid candidate from “developability-flagged” to “approvable for chronic pediatric administration”.

Why H01 cares directly

H01’s current lead v5.2__aq3__adamantyl__CONHOH__-Cl sits exactly under this rubric. The hydroxamic acid is mech-anchor (STRC h01 Phase 5k-WT Matched Ensemble APBS 2026-04-25 formal-anion preference depends on CONHO⁻ at K1141 NZ) and per h01 Phase 7I v52 Combined Boltz-2 Analysis 2026-04-26 now demoted from “lead” to “mech-proof reference compound” — but any analog retaining the CONHOH head (or its metabolic precursor CONHOMe prodrug, see Phase 7I) inherits Givinostat’s regulatory script.

Concrete IND-prep additions H01 has not yet planned:

  • mARC1/2 in-vitro assay (wet-lab, not compute) on v5.2__aq3__adamantyl__CONHOH__-Cl and v5.3__aq3__adamantyl__CONHOMe__-Cl/CN candidates. Vendor: any specialty ADME CRO with mARC capability (DR3 vendor menu has options).
  • Cross-link to existing Hydroxamic Acid Divalent Cation Liability — that note covers the off-target ion-channel chelation axis; this note covers the metabolic-safety axis. Both must clear independently.

For paper §7 (safety / developability):

  • Cite Givinostat (Duvyzat) FDA approval 2024 as the regulatory precedent that makes the chemotype admissible.
  • Frame the H01 candidate’s metabolic-clearance hypothesis explicitly (mARC-mediated reduction; not CYP-mediated oxidation).
  • Note that mARC1/2 expression varies across tissues; cochlear mARC expression is not characterized in the literature — this is a knowable gap that DR1 / DR3 do not close.

Cross-cutting note on intratympanic dosing

A counterargument: intratympanic delivery (per DR5 — Intratympanic Round-Window Small-Molecule Delivery) bypasses systemic exposure almost entirely. Hepatic-metabolism concerns are dramatically reduced when a 6% Poloxamer-407 hydrogel deposits microgram quantities behind the round window with limited systemic spillover.

This does not eliminate the regulatory ask — FDA still expects characterized metabolism for any chronic-use small molecule, and the systemic spillover from intratympanic depot is non-zero — but it softens the hepatotoxicity bar relative to oral Givinostat dosing.

The defensible regulatory position: “the candidate uses the Givinostat mARC1/2 metabolic route, AND the intratympanic-depot route limits systemic exposure to microgram-day levels, well below any plausible hepatotoxicity threshold.”

Connections

Graph View

Backlinks